Uncategorized

BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication

Published

on

BioMarin’s discontinued drug showed biomarker benefits in a Phase 3 study for ENPP1 deficiency but these failed to translate to clinical improvements.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version